Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Buy
71
RYTM Quote, Financials, Valuation and Earnings
Last price:
$90.73
Seasonality move
:
17.77%
Day range:
$88.92 - $92.14
52-week range:
$40.61 - $94.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
41.24x
P/B ratio:
318.47x
Volume:
727.4K
Avg. volume:
866.8K
1-year change:
69.68%
Market cap:
$6B
Revenue:
$130.1M
EPS (TTM):
-$2.81
Analysts' Opinion
-
Consensus RatingRhythm Pharmaceuticals has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $103.64, Rhythm Pharmaceuticals has an estimated upside of 13.35% from its current price of $91.44.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $80.00 representing 12.51% downside risk from its current price of $91.44.
Fair Value
-
According to the consensus of 10 analysts, Rhythm Pharmaceuticals has 13.35% upside to fair value with a price target of $103.64 per share.
RYTM vs. S&P 500
-
Over the past 5 trading days, Rhythm Pharmaceuticals has overperformed the S&P 500 by 2.68% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Rhythm Pharmaceuticals does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Rhythm Pharmaceuticals has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Rhythm Pharmaceuticals reported revenues of $32.7M.
Earnings Growth
-
Rhythm Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Rhythm Pharmaceuticals reported earnings per share of -$0.81.
Enterprise value:
5.9B
EV / Invested capital:
--
Price / LTM sales:
41.24x
EV / EBIT:
--
EV / Revenue:
42.84x
PEG ratio (5yr expected):
-0.41x
EV / Free cash flow:
-51.67x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$122.7M
Return On Assets:
-47.31%
Net Income Margin (TTM):
-123.26%
Return On Equity:
-116.92%
Return On Invested Capital:
-116.92%
Operating Margin:
-143.73%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $33.6M | $91.9M | $136.9M | $26M | $32.7M | |
| Gross Profit | $30.3M | $81.2M | $122.7M | $23.2M | $29.1M | |
| Operating Income | -$179M | -$271.7M | -$172.6M | -$139.9M | -$47M | |
| EBITDA | -$170.5M | -$255.5M | -$146.3M | -$135.9M | -$43.6M | |
| Diluted EPS | -$3.35 | -$4.63 | -$2.81 | -$2.35 | -$0.81 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $412.1M | $253.4M | $317.8M | $235.8M | $369.3M | |
| Total Assets | $422.2M | $284.8M | $345.7M | $258.7M | $386.7M | |
| Current Liabilities | $16.9M | $47.3M | $46M | $54.2M | $111.8M | |
| Total Liabilities | $41.3M | $49.1M | $125.9M | $197.1M | $223.6M | |
| Total Equity | $380.9M | $235.8M | $219.8M | $61.6M | $163.1M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$156.2M | -$140.5M | -$113.5M | -$40.7M | -$40.4M | |
| Cash From Investing | -$26M | $5.9M | -$53.4M | $30.1M | $24.8M | |
| Cash From Financing | $213.3M | $78.7M | $219.5M | $4.2M | $32.5M | |
| Free Cash Flow | -$160.4M | -$180.5M | -$113.5M | -$80.7M | -$40.4M | |
RYTM
Sector
Market Cap
$6B
$34.4M
Price % of 52-Week High
96.46%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
69.68%
-37.36%
Beta (5-Year)
2.265
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$83.28
200-day SMA
Buy
Level
$58.40
Bollinger Bands (100)
Buy
Level
52.23 - 69.71
Chaikin Money Flow
Buy
Level
3.4M
20-day SMA
Buy
Level
$71.26
Relative Strength Index (RSI14)
Buy
Level
79.96
ADX Line
Buy
Level
33.8
Williams %R
Sell
Level
-9.8824
50-day SMA
Buy
Level
$65.95
MACD (12, 26)
Buy
Level
24.20
25-day Aroon Oscillator
Buy
Level
56
On Balance Volume
Neutral
Level
8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.5622)
Sell
CA Score
(Annual)
Level (-3.4835)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (4.2409)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Stock Forecast FAQ
In the current month, RYTM has received 10 Buy ratings 0 Hold ratings, and 0 Sell ratings. The RYTM average analyst price target in the past 3 months is $103.64.
-
Where Will Rhythm Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Rhythm Pharmaceuticals share price will rise to $103.64 per share over the next 12 months.
-
What Do Analysts Say About Rhythm Pharmaceuticals?
Analysts are divided on their view about Rhythm Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Rhythm Pharmaceuticals is a Sell and believe this share price will drop from its current level to $80.00.
-
What Is Rhythm Pharmaceuticals's Price Target?
The price target for Rhythm Pharmaceuticals over the next 1-year time period is forecast to be $103.64 according to 10 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is RYTM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Rhythm Pharmaceuticals is a Buy. 10 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RYTM?
You can purchase shares of Rhythm Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Rhythm Pharmaceuticals shares.
-
What Is The Rhythm Pharmaceuticals Share Price Today?
Rhythm Pharmaceuticals was last trading at $90.73 per share. This represents the most recent stock quote for Rhythm Pharmaceuticals. Yesterday, Rhythm Pharmaceuticals closed at $91.44 per share.
-
How To Buy Rhythm Pharmaceuticals Stock Online?
In order to purchase Rhythm Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
